Induced stem cells

ViaCyte to Present at the Jefferies Virtual Healthcare Conference

Thursday, May 28, 2020 - 2:00pm

SAN DIEGO, May 28, 2020 /PRNewswire/ -- ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind, Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9.

Key Points: 
  • SAN DIEGO, May 28, 2020 /PRNewswire/ -- ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind, Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9.
  • ViaCyte is the first company to demonstrate production of C-peptide, a biomarker for insulin, in patients with type 1 diabetes receiving a stem cell-derived islet replacement.
  • During the presentation, Dr. Laikind will discuss ViaCyte's leadership in discovering and developing novel cell replacement therapies to treat human diseases.
  • With CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 pluripotent stem cell line.

Frequency Therapeutics to Present at Upcoming Investor Conferences

Wednesday, May 27, 2020 - 1:00pm

A replay of each presentation will be posted on the Frequency website for at least 30 days following each event.

Key Points: 
  • A replay of each presentation will be posted on the Frequency website for at least 30 days following each event.
  • Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases.
  • The Companys progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies.
  • The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including a discovery program in multiple sclerosis.

Insights into North America's Biobanks Market 2020, Featuring Key Player Profiles Including Atlanta Biologicals Inc., BioLifeSolutions Inc. and Thermo Fisher Scientific Inc.

Friday, May 22, 2020 - 10:15pm

Stem cell practices are on the rise and are contributing to the development of new solutions for various diseases.

Key Points: 
  • Stem cell practices are on the rise and are contributing to the development of new solutions for various diseases.
  • Several advancements have been made in regenerative medicine through stem cell technology over the past decade.
  • Thus, it has become one of the vital treatment methods for diseases, such as Alzheimer's, diabetes, cancer, and rare genetic diseases.
  • In order to benefit from the existing therapies, umbilical cord cells and other stem cells are preserved in Biobanks.

HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's disease treatment

Friday, May 22, 2020 - 3:29am

HONG KONG, May 22, 2020 /PRNewswire/ -- Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.

Key Points: 
  • HONG KONG, May 22, 2020 /PRNewswire/ -- Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.
  • They found that the transplantation of these nerve cells into rats with Parkinson's disease progressively improved their symptoms, with the new cells replacing damaged nerve cells around the transplantation site.
  • This novel invention provides promising insights into stem cell therapies and offers hope of a new treatment for Parkinson's disease.
  • The chemicals used may stimulate the growth of cancer cells and increase the risk of developing tumours after transplantation to human body.

HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's disease treatment

Friday, May 22, 2020 - 3:24am

HONG KONG, May 21, 2020 /PRNewswire/ -- Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.

Key Points: 
  • HONG KONG, May 21, 2020 /PRNewswire/ -- Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.
  • They found that the transplantation of these nerve cells into rats with Parkinson's disease progressively improved their symptoms, with the new cells replacing damaged nerve cells around the transplantation site.
  • This novel invention provides promising insights into stem cell therapies and offers hope of a new treatment for Parkinson's disease.
  • The chemicals used may stimulate the growth of cancer cells and increase the risk of developing tumours after transplantation to human body.

Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy

Wednesday, May 20, 2020 - 1:00pm

FT538 is the fourth off-the-shelf, iPSC-derived NK cell product candidate from the Companys proprietary iPSC product platform cleared for clinical investigation by the FDA.

Key Points: 
  • FT538 is the fourth off-the-shelf, iPSC-derived NK cell product candidate from the Companys proprietary iPSC product platform cleared for clinical investigation by the FDA.
  • Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body.
  • Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.

Meso Numismatics Provides Update On Global Stem Cell Transaction

Tuesday, May 19, 2020 - 12:55pm

LAS VEGAS, NV, May 19, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Meso Numismatics, Inc. (Meso Numismatics or the Company) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, announced today that the Company has successfully made its first $50,000 payment to Global Stem Cells Group (GSCG), as per the Companys updated LOI amendment, dated April 22nd, 2020, to complete its acquisition of the stem cell operation.

Key Points: 
  • LAS VEGAS, NV, May 19, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Meso Numismatics, Inc. (Meso Numismatics or the Company) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, announced today that the Company has successfully made its first $50,000 payment to Global Stem Cells Group (GSCG), as per the Companys updated LOI amendment, dated April 22nd, 2020, to complete its acquisition of the stem cell operation.
  • We look forward to completing the acquisition of Global Stem Cells Group, stated David Christensen, President of MSSV.
  • We are very optimistic about the opportunities that stem cell technology can offer to the world and confident that Global Stem Cells Group has the ability to help facilitate these therapies on a large scale.
  • Meso Numismatics is a numismatic company specializing in the Meso Region, including Central America and the Caribbean.

Lineage Cell Therapeutics to Participate in Maxim Group and M-Vest COVID-19 Virtual Conference Series on May 27, 2020

Tuesday, May 19, 2020 - 1:00pm

Interested investors can access the discussion as part of the Maxim Group and M-Vest COVID-19 Virtual Conference Series .

Key Points: 
  • Interested investors can access the discussion as part of the Maxim Group and M-Vest COVID-19 Virtual Conference Series .
  • In this iteration of our ongoing M-Vest Infectious Disease Virtual Conference Series, we focus in on two key areas related to the ongoing pandemic; cell based therapies and testing.
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
  • With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.

Lineage Cell Therapeutics to Present at 2020 Solebury Trout Virtual Investor Conference on May 26, 2020

Monday, May 18, 2020 - 1:00pm

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the 2020 Solebury Trout Virtual Investor Conference on May 26, 2020 at 2:30 pm Eastern Time.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the 2020 Solebury Trout Virtual Investor Conference on May 26, 2020 at 2:30 pm Eastern Time.
  • Interested investors can access the live presentation as part of the Solebury Trout Virtual Conference Series .
  • Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.
  • With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials.

R3 Stem Cell International Now Offering Enhanced Autism Stem Cell Program in Mexico

Monday, May 18, 2020 - 5:00am

SCOTTSDALE, Ariz., May 18, 2020 /PRNewswire-PRWeb/ -- R3 Stem Cell International is now offering an enhanced autism stem cell therapy program at its Tijuana regenerative clinic.

Key Points: 
  • SCOTTSDALE, Ariz., May 18, 2020 /PRNewswire-PRWeb/ -- R3 Stem Cell International is now offering an enhanced autism stem cell therapy program at its Tijuana regenerative clinic.
  • R3 Stem Cell International's enhanced program provides umbilical cord derived stem cell therapy for patients, with total cell counts for the treatment ranging between 90 million up to 200 million live stem cells.
  • As with all R3 Stem Cell International procedures, R3 takes care of concierge escort transportation from San Diego to the clinic, which is only 20 minutes from the SD International Airport.
  • About R3 Stem Cell International: After 14,000 stem cell procedures in the US, R3 opened R3 Stem Cell International.